SOTAC

Sotac Pharmaceuticals Ltd Share Price

 

Stock Hit Upper Circuit

 

Start SIP in SOTAC

Start SIP

Performance

  • Low
  • ₹118
  • High
  • ₹130
  • 52 Week Low
  • ₹88
  • 52 Week High
  • ₹152
  • Open Price₹118
  • Previous Close₹123
  • Volume3,600

Investment Returns

  • Over 1 Month -6.46%
  • Over 3 Month + 13.89%
  • Over 6 Month -6.26%
  • Over 1 Year + 18.31%

Smart Investing Starts Here Start SIP with Sotac Pharmaceuticals Ltd for Steady Growth!

Invest Now

Sotac Pharmaceuticals Ltd Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 17.8
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 143
  • P/B Ratio
  • 3
  • Average True Range
  • 5.26
  • EPS
  • 6.95
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 2.03
  • RSI
  • 45.07
  • MFI
  • 77.26

Sotac Pharmaceuticals Ltd Financials

Sotac Pharmaceuticals Ltd Technicals

EMA & SMA

Current Price
₹129.55
+ 6.15 (4.98%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹128.97
  • 50 Day
  • ₹126.63
  • 100 Day
  • ₹125.45
  • 200 Day
  • ₹125.57

Resistance and Support

123.4 Pivot Speed
  • R3 123.40
  • R2 123.40
  • R1 123.40
  • S1 123.40
  • S2 123.40
  • S3 123.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sotac Pharmaceuticals Ltd has an operating revenue of Rs. 121.79 Cr. on a trailing 12-month basis. An annual revenue de-growth of -3% needs improvement, Pre-tax margin of 11% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 86 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sotac Pharmaceuticals Ltd Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results & Others To consider other business matters. Final Dividend of Rs. 0.1 per equity share.
2025-05-28 Audited Results, Dividend & Others To consider other business matters. Final Dividend of Rs. 0.1 per equity share.
2024-10-29 Quarterly Results
2024-08-13 Quarterly Results
2024-05-17 Audited Results & Others To consider other business matters Final Dividend of Rs. 0.1 per equity share.
Date Purpose Remarks
2025-09-19 FINAL Rs.0.00 Final Dividend of Rs. 0.1 per equity share.
View Sotac Pharmaceuticals Ltd Dividend History Arrow

Sotac Pharmaceuticals Ltd F&O

Sotac Pharmaceuticals Ltd Shareholding Pattern

72.85%
16.14%
5.12%
5.89%

About Sotac Pharmaceuticals Ltd

  • NSE Symbol
  • SOTAC
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Sharadkumar Dashrathbhai Patel
  • ISIN
  • INE0O2D01012

Similar Stocks to Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Ltd FAQs

Sotac Pharmaceuticals Ltd share price is ₹129 As on 30 December, 2025 | 16:35

The Market Cap of Sotac Pharmaceuticals Ltd is ₹143.2 Cr As on 30 December, 2025 | 16:35

The P/E ratio of Sotac Pharmaceuticals Ltd is 17.8 As on 30 December, 2025 | 16:35

The PB ratio of Sotac Pharmaceuticals Ltd is 3 As on 30 December, 2025 | 16:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23